News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Epirus is set to file its Remicade biosimilar in 2017 and says the $3bn market will remain a large opportunity despite growing entrants in infliximab development.
Cell Therapy Catapult, the UK fund for gene therapy, broke ground yesterday on a £55m bio-manufacturing centre in Stevenage, UK.
The European Generic and Biosimilar Medicines Association (EGA) and the Spanish Generic Medicines Association (AESEG) today revealed plans to remove market barriers to biosimilars and small molecule generics and create thousands of jobs.